Abstract 358P
Background
The prognosis of patients with recurrent malignant glioma (rMG) is quite poor. According to the NCCN guidelines, bevacizumab is recommended drug for rMG. Anlotinib is a multitarget tyrosine kinase inhibitor that can inhibit tumor angiogenesis and tumor cell growth. We report results from this retrospective study to determine the efficacy and tolerability of Anlotinib plus temozolomide (TMZ) as a first-line treatment for rMG.
Methods
A total of 30 eligible patients who relapsed from the standard chemoradiotherapy regimen (TMZ and radiotherapy) or had macroscopic residual tumor after surgery because of tumor located in the eloquent brain areas were enrolled in this study between March 2018 and January 2021. Patients were subjected to a concurrent treatment of Anlotinib (12mg qd) and TMZ (200mg/m2, 5 days on with 23 days off) until disease progression or intolerable toxicity. Efficacy was evaluated using Response Assessment in Neuro-Oncology criteria for high-grade glioma. Safety was assessed using NCI-CTCAE 4.0. Survival was estimated with the Kaplan-Meier curve and log-rank test.
Results
All patients were eligible for efficacy analysis. The objective response rate (ORR) was 76.7%. The disease control rate (DCR) was 90%. The median progress-free survival time was 8.3 months. The median overall survival was 10.8 months. The most common treatment-related adverse events were hand-foot syndrome (43.3%), leukopenia (40%), transaminase elevation (40%), hypertension (30%), thrombocytopenia (30%), albuminuria (26.7%), hyperbilirubin (36.7%), anemia (23.3%), neutropenia (16.7%) and gastrointestinal reaction (13.3%). The rate of grade 3/4 AE was relatively low, including hand-foot syndrome 6.7% (2/30), thrombocytopenia 6.7% (2/30), and hyperbilirubin 3.3% (1/30).
Conclusions
Anlotinib combined with TMZ was effective in terms of PFS, ORR, and DCR, and was well tolerated. Further randomized controlled clinical studies are needed to confirm the efficacy of Anlotinib combined with TMZ for the treatment of rMG.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.